UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Passive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomes

Journal of drug targeting, 2016-11, Vol.24 (9), p.797-804

2016

Volltextzugriff (PDF)

Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

Molecular cancer therapeutics, 2006-07, Vol.5 (7), p.1854-1863

2006

Volltextzugriff (PDF)

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts

Leukemia research, 2010-09, Vol.34 (9), p.1214-1223

2010

Volltextzugriff (PDF)

Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo

Expert opinion on drug delivery, 2010-12, Vol.7 (12), p.1329-1341

2010

Volltextzugriff (PDF)

Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo

Molecular cancer therapeutics, 2009-08, Vol.8 (8), p.2266-2275

2009

Volltextzugriff (PDF)

Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates

Journal of medicinal chemistry, 2008-06, Vol.51 (11), p.3288-3296

2008

Volltextzugriff (PDF)

Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo

Biochimica et biophysica acta, 2007-03, Vol.1768 (3), p.678-687

2007

Volltextzugriff (PDF)

Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes

International journal of pharmaceutics, 2007-06, Vol.337 (1), p.219-228

2007

Volltextzugriff (PDF)

Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity

Journal of controlled release, 2005-06, Vol.105 (1), p.89-105

2005

Volltextzugriff (PDF)

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties

International journal of nanomedicine, 2019-05, Vol.14, p.3819-3830

2019

Volltextzugriff (PDF)

A comparison of liposomal formulations of doxorubicin with drug administered in free form: Changing toxicity profiles

Drug safety, 2001, Vol.24 (12), p.903-920

2001

Volltextzugriff (PDF)

Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts

Leukemia & lymphoma, 2010-08, Vol.51 (8), p.1536-1542

2010

Volltextzugriff (PDF)

Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios

Oncology research, 2007-01, Vol.16 (8), p.361

2007

Volltextzugriff (PDF)

Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals

Nanomedicine, 2020-11, Vol.30, p.102275, Article 102275

2020

Volltextzugriff (PDF)

Intra and Inter-Molecular Interactions Dictate the Aggregation State of Irinotecan Co-Encapsulated with Floxuridine Inside Liposomes

Pharmaceutical research, 2008-07, Vol.25 (7), p.1702-1713

2008

Volltextzugriff (PDF)

Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes

Biochimica et biophysica acta, 2002-04, Vol.1561 (2), p.188-201

2002

Volltextzugriff (PDF)

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy

Leukemia research, 2009-01, Vol.33 (1), p.129-139

2009

Volltextzugriff (PDF)

Abstract 287: CPX-351 cytotoxicity against fresh AML blasts is increased for FLT3-ITD+ cells and correlates with drug uptake and clinical outcomes

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.287-287

2016

Volltextzugriff (PDF)

Liposomal Doxorubicin

Journal of drug targeting, 1996, Vol.4 (3), p.129-140

1996

Volltextzugriff (PDF)

The Use of Radioactive Marker as a Tool to Evaluate the Drug Release in Plasma and Particle Biodistribution of Block Copolymer Nanoparticles

Journal of Drug Delivery, 2011-01, Vol.2011, p.349206-9

2011

Volltextzugriff (PDF)

Abstract 1087: CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1087-1087

2017

Volltextzugriff (PDF)

Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation

Blood, 2016-12, Vol.128 (22), p.5124-5124

2016

Volltextzugriff (PDF)

Abstract B34: Coordinated delivery of anticancer drug combinations incorporating molecularly targeted agents provides markedly increased plasma drug exposure, decreased toxicity and increased efficacy in preclinical tumor models

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B34-B34

2015

Volltextzugriff (PDF)

CPX-351 Exhibits Potent and Direct Ex Vivo Cytotoxicity Against AML Blasts With Enhanced Efficacy for Cells Harboring the FLT3-ITD Mutation

Leukemia research, 2017-02, Vol.53, p.39-49

2017

Volltextzugriff (PDF)

Quantitative Whole Body Autoradiography (QWBA) Analysis Reveals That CPX-351 Shifts the Exposure of Cytarabine (Cyt) and Daunorubicin (Daun) Away from Many Tissues While Providing Prolonged Exposure to Cytotoxic Drug Concentrations in the Bone Marrow Compared to Conventional Free Drug Administration

Blood, 2014-12, Vol.124 (21), p.3740-3740

2014

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

Englisch
(53)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(35)
Science & Technology
(35)
Animals
(25)
Liposomes
(18)
Humans
(17)
Mice
(16)
Biological And Medical Sciences
(14)
Pharmacology & Pharmacy
(13)
Biochemistry & Molecular Biology
(12)
Medical Sciences
(11)
Pharmacology. Drug Treatments
(11)
Oncology
(9)
Drug Delivery
(8)
Female
(8)
Antineoplastic Agents
(7)
Camptothecin - Analogs & Derivatives
(7)
Cell Line, Tumor
(7)
Dose-Response Relationship, Drug
(7)
Drug Compounding
(7)
Synergy
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Passive and semi-active targeting of bone marrow and leukemia cells using anionic low cholesterol liposomes

Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts

Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo

Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo

Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates

Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo

Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes

Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties

A comparison of liposomal formulations of doxorubicin with drug administered in free form: Changing toxicity profiles

Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts

Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios

Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals

Intra and Inter-Molecular Interactions Dictate the Aggregation State of Irinotecan Co-Encapsulated with Floxuridine Inside Liposomes

Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy

Abstract 287: CPX-351 cytotoxicity against fresh AML blasts is increased for FLT3-ITD+ cells and correlates with drug uptake and clinical outcomes

Liposomal Doxorubicin

The Use of Radioactive Marker as a Tool to Evaluate the Drug Release in Plasma and Particle Biodistribution of Block Copolymer Nanoparticles

Abstract 1087: CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD

Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation

Abstract B34: Coordinated delivery of anticancer drug combinations incorporating molecularly targeted agents provides markedly increased plasma drug exposure, decreased toxicity and increased efficacy in preclinical tumor models

CPX-351 Exhibits Potent and Direct Ex Vivo Cytotoxicity Against AML Blasts With Enhanced Efficacy for Cells Harboring the FLT3-ITD Mutation

Quantitative Whole Body Autoradiography (QWBA) Analysis Reveals That CPX-351 Shifts the Exposure of Cytarabine (Cyt) and Daunorubicin (Daun) Away from Many Tissues While Providing Prolonged Exposure to Cytotoxic Drug Concentrations in the Bone Marrow Compared to Conventional Free Drug Administration

Suchergebnisse filtern